Aura Biosciences, Inc. AURA
6.98 USD -0.16 (-2.24%)
Regular-session close
6.98 0.00 0.00%
After hours · Nov 19, 4:01 PM ET
6.83 Day range 7.24
4.97 52-week range 8.90
- YTD
- +28.07%
- 1 year
- +29.26%
News
benzinga.com OXB Confirms Manufacturing And Supply Partnership With Aura Biosciences For Late-Stage Development And Manufacturing Activities Of Belzupacap Sarotalocan Partnership established earlier this year supports Aura’s Phase 3 virus-like drug conjugates (VDC) client programme and preparations for potential future commercial supplyProgramme builds on OXB’s…
globenewswire.com OXB confirms partnership with Aura Biosciences supporting Phase 3 development and future commercial supply of lead oncology candidate Oxford, UK – 17 November 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today confirm its manufacturing and supply partnership with Aura Biosciences, Inc.…
zacks.com Here's Why You Should Add AURA Stock to Your Portfolio Now Aura completes phase III enrollment for bel-sar, with pivotal data expected in 2027 and additional ocular cancer programs expanding its growth potential.
zacks.com Wall Street Analysts Believe Aura Biosciences (AURA) Could Rally 119.61%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 119.6% in Aura Biosciences (AURA). While the effectiveness of this highly sought-after metric is questionable,…benzinga.com Aura Biosciences Q3 EPS $(0.29) Beats $(0.37) Estimate Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.37) by 21.62 percent. This is a 27.5 percent increase over losses of…
globenewswire.com Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights Phase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visits Established relationship with industry-leading CDMO providing designated manufacturing…
globenewswire.com Aura Biosciences to Participate in Upcoming Investor Conference BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients…
seekingalpha.com Aura Biosciences: A Pivotal Trial Engineered With Room To Spare Aura Biosciences offers a de-risked, fully funded play on the bel-sar for early choroidal melanoma, with pivotal Phase 3 data expected in 2027. AURA's cash position of $323.8 million as of June 2026…
seekingalpha.com Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
defenseworld.net Aura Biosciences, Inc. $AURA Shares Bought by Frazier Life Sciences Management L.P. Frazier Life Sciences Management L.P. grew its position in shares of Aura Biosciences, Inc. (NASDAQ: AURA) by 39.2% during the undefined quarter, according to the company in its most recent…
globenewswire.com Aura Biosciences to Participate in Upcoming Investor Conference BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients…
defenseworld.net BlackRock Inc. Makes New Investment in Aura Biosciences, Inc. $AURA BlackRock Inc. bought a new stake in shares of Aura Biosciences, Inc. (NASDAQ: AURA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange…
globenewswire.com Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative…
defenseworld.net ADAR1 Capital Management LLC Acquires Shares of 130,152 Aura Biosciences, Inc. $AURA ADAR1 Capital Management LLC bought a new position in shares of Aura Biosciences, Inc. (NASDAQ: AURA) in the second quarter, according to the company in its most recent filing with the Securities and…
seekingalpha.com Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval Aura Biosciences, Inc. is focused on late-stage development of Bel-sar for early choroidal melanoma, addressing significant unmet medical needs. The Phase 3 CoMpass trial is fully enrolled, with…
globenewswire.com Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ…
newsfilecorp.com Auranova and Kenorland Announce Large Intrusion-Related Gold Discovery at the South Uchi Project, Ontario Vancouver, British Columbia--(Newsfile Corp. - June 17, 2026) - Auranova Resources Inc. (TSXV: AURA) ("Auranova" or the "Company") and Kenorland Minerals Ltd. ("Kenorland") are pleased to announce…
globenewswire.com Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026…
marketbeat.com Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances Aura Biosciences NASDAQ: AURA is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal…
marketbeat.com Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data Aura Biosciences NASDAQ: AURA executives outlined the company's strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the…
globenewswire.com Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors…
globenewswire.com Aura Biosciences to Participate in Upcoming Investor Conferences BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ…
